Does discontinuing glucagon‑like peptide‑1 (GLP‑1) receptor agonist therapy increase the risk of stroke and cardiovascular disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Discontinuing GLP-1 Receptor Agonists Increases Cardiovascular Risk

Yes, I can confirm that discontinuing GLP-1 receptor agonist therapy is associated with increased cardiovascular risk, including stroke and major adverse cardiovascular events (MACE), based on recent real-world evidence. This finding directly contradicts the protective cardiovascular benefits these medications provide when continued.

The Evidence on Discontinuation Risk

The most compelling evidence comes from a 2023 real-world study that tracked 550 patients with type 2 diabetes over a median follow-up of 3.6-5.0 years 1. In multivariable analysis treating GLP-1RA as a time-dependent covariate, discontinuation increased MACE risk by 240-340% (HR 2.71-3.40, p<0.002) compared to continued therapy. This elevated risk occurred in both primary prevention patients (no prior cardiovascular disease) and secondary prevention patients (established cardiovascular disease) 1.

Importantly, this increased risk occurred despite the fact that patients who discontinued had initially experienced the same metabolic improvements as those who continued. The key difference was the cessation of therapy itself 1.

What Happens After Stopping GLP-1RAs

When GLP-1 receptor agonists are discontinued, multiple adverse metabolic consequences occur rapidly:

  • Weight regain: 60-90% of lost weight returns within 12 months 2
  • Glycemic deterioration: HbA1c returns to baseline within 12-18 months 2
  • Blood pressure increases: Returns to pre-treatment levels within approximately 12 months 2
  • Lipid profile worsening: Reversal of improvements within 12 months 2

These metabolic reversals translate directly into cardiovascular risk. Early discontinuation (within the first year) is specifically associated with increased risks of coronary artery disease and heart failure compared with continued therapy 2.

Mechanisms Behind the Increased Risk

The cardiovascular risk elevation after discontinuation likely stems from multiple factors 3, 2:

  1. Loss of direct cardiovascular protection: GLP-1RAs provide benefits beyond glucose control, including anti-inflammatory effects, blood pressure reduction, and improved endothelial function
  2. Metabolic yo-yo effect: Repeated cycles of weight loss and regain, along with HbA1c fluctuations, are independent risk factors for cardiovascular and microvascular events
  3. Lack of plaque-stabilizing effects: Unlike statins, GLP-1RAs may not provide lasting anti-atherosclerotic effects after discontinuation, potentially contributing to acute cardiovascular risk elevation 3
  4. Reactivation of orexigenic pathways: Biological adaptations to weight loss become reactivated, driving weight regain and metabolic deterioration 2

Context: The Protective Effects When Continued

To understand the magnitude of risk from discontinuation, consider what you lose. GLP-1 receptor agonists with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide) reduce MACE by 12-16% when continued 4, 5, 6. They specifically reduce:

  • Cardiovascular death by 12% 6
  • Fatal/non-fatal stroke by 16% 6
  • Fatal/non-fatal MI by 9% 6
  • All-cause mortality by 11% 6

Current guidelines from the ADA/EASD (2020) and ESC (2024) give Class I, Level A recommendations for GLP-1RAs in patients with type 2 diabetes and established atherosclerotic cardiovascular disease to reduce MACE 4, 7. The 2024 ESC guidelines even extend this recommendation to overweight/obese patients with chronic coronary syndrome without diabetes (Class IIa, Level B) 7.

Clinical Implications and Management

Discontinuation should be considered a high-risk clinical transition, not a treatment endpoint 2. When patients must stop GLP-1RA therapy:

  1. Implement structured multidisciplinary follow-up combining pharmacological alternatives, intensive lifestyle intervention, and psychological support 2
  2. Monitor cardiovascular risk factors aggressively: Check HbA1c, blood pressure, and lipids within 3 months of discontinuation
  3. Consider alternative cardioprotective agents: If stopping due to side effects or cost, transition to SGLT2 inhibitors (which also have Class I cardiovascular benefit recommendations) 4, 7
  4. Avoid tapering strategies: No validated tapering protocols exist; abrupt cessation appears to be the norm in clinical practice 2

Common Pitfalls

  • Assuming metabolic benefits persist after stopping: They don't—expect near-complete reversal within 12-18 months 2
  • Discontinuing in high-risk patients due to minor side effects: Gastrointestinal symptoms usually improve with dose titration and time 8
  • Stopping therapy once glycemic targets are achieved: The cardiovascular benefits are independent of baseline or target HbA1c 4, 7
  • Failing to counsel patients about discontinuation risks: Patients need to understand this is long-term therapy for cardiovascular protection, not just glucose control

The Bottom Line

The study you referenced is accurate and supported by converging evidence. Stopping GLP-1 receptor agonists eliminates their cardiovascular protective effects and may acutely increase risk of stroke and MACE, particularly in the first year after discontinuation 1, 2. This risk elevation occurs through rapid reversal of metabolic improvements and loss of direct cardiovascular protective mechanisms. For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, GLP-1RAs should be viewed as indefinite therapy for cardiovascular risk reduction, not temporary glucose management 4, 7.

References

Related Questions

In a patient with an HbA1c of 5.9% who is at a normal weight and currently taking a GLP‑1 receptor agonist, should the GLP‑1 therapy be continued or discontinued?
Does abruptly stopping tirzepatide affect serum uric acid levels?
Should I stop gliclazide when starting a GLP‑1 receptor agonist?
How do GLP‑1 receptor agonists compare to dual GLP‑1/GIP receptor agonists (e.g., tirzepatide) for treating type 2 diabetes or obesity?
In a 63‑year‑old man with type 2 diabetes for 20 years, A1C 10 % and normal renal function who is taking metformin, dapagliflozin, tirzepatide, and gliclazide, why should gliclazide be stopped or reduced?
How does the opioid system affect attention?
In a patient with schizophrenia currently treated with olanzapine who is experiencing worsening paranoia, how should the olanzapine dose be adjusted and what additional management steps are recommended?
What are the recommended antihistamines and dosing for infants and children with allergic conditions?
What are the assessment signs for bacterial meningitis?
Do patients taking a GLP‑1 receptor agonist need to continue it lifelong?
What is the recommended duloxetine regimen for managing anxiety, depression, and neuropathic pain during pregabalin withdrawal?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.